Joris's story: What Is Biliary Atresia? December 1 Is #BAAwarenessDay. To help raise awareness of biliary atresia (BA) over the next few days we are sharing Joris's story. Hear from Maria, the mother of Joris, as she tells how she learnt Joris had biliary atresia; the Importance of early diagnosis; the challenges of liver transplantation and the Importance of support. To see the full video go to: https://lnkd.in/ecPmRCym #BAAwarenessDay #RareliverDisease #pediatricliver
Ipsen
Fabrication de produits pharmaceutiques
Paris, Île-de-France 287 515 abonnés
À propos
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
- Site web
-
http://www.ipsen.com
Lien externe pour Ipsen
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 5 001-10 000 employés
- Siège social
- Paris, Île-de-France
- Type
- Société cotée en bourse
- Domaines
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins et Primary Care
Lieux
Employés chez Ipsen
-
James Frey
GLOBAL PHARMACEUTICALS | Go-To-Market Strategy ~ Brand Development ~ New Product Launch ~ Partnerships & Alliances
-
Frederic Rivart
Consultant IT et Cyber Sécurité
-
Jean-Marc Issa
Head of End User Operations and Services
-
Josep Catlla
Executive Vice President & Chief Corporate Affairs Officer
Nouvelles
-
Every year, thousands of infants are born with Biliary Atresia (BA) a rare, but life-threatening liver disease. It blocks bile flow and can lead to liver failure if left untreated. Early signs, such as prolonged jaundice and pale stools are often missed. But with timely diagnosis and appropriate surgery, lives can be saved. Swipe ➡️ Learn more about Biliary Atresia: https://lnkd.in/eFXH-Q9a
-
400,000 people will hear "you have RCC" this year. Most have never heard of it before. Renal Cell Carcinoma (RCC) is the most common kidney cancer, often symptomless until advanced. With late-stage survival at just 12%, time isn't guaranteed. When treatment options are limited, bold science becomes essential. At Ipsen, we’re partnering with the healthcare and patient community to drive innovation and optimize care for people living with advanced RCC. Learn more about our areas of focus: https://lnkd.in/ezViFm4D
-
Three clues… can you name the role? Meet Prince Korah, Senior Director in Pharmaceutical Development. He shapes molecules into medicines that don’t just work in the lab but in real life. From early development to clinical delivery, Prince ensures each treatment meets the highest standards before it reaches patients. Design for stability. Simplify where possible. Always center the science. Glad to have you leading the way, Prince 👑 Learn more about Prince Korah: https://lnkd.in/eWwvh7cx
-
-
Anyone can promise net zero. Not everyone can prove it. Ipsen's greenhouse gas reduction targets are certified by Science Based Targets initiative the global framework that ensures companies align with the 1.5°C goal set by climate science. Our certification covers all three scopes: direct operations (Scope 1), purchased energy (Scope 2), and our entire value chain including suppliers, partners, and product use (Scope 3). Because real progress means holding everyone (including ourselves) to science-based standards. 💚
-
You don't just become a great place to work. You earn it. 16 new Ipsen locations across Canada, USA, Mexico, Colombia, Brazil, Ireland, The Netherlands, Italy, Algeria, Tunisia, Sweden, Lithuania, Poland, Greece, UAE, and Saudi Arabia just earned Great Place To Work certification. That brings us to 30 externally certified locations. With 1 evidence: Culture matters at Ipsen 💙 Learn more: https://lnkd.in/etb757mV
-
Because geography shouldn't decide who gets treated. Our global footprint isn't just about numbers. It's about ensuring patients in 105+ countries can access the treatments they need. With 5,300+ colleagues across 35+ countries and 3 global R&D sites, we're working to close the gap between innovation and impact. Oncology. Rare Disease. Neuroscience. Three therapeutic areas. One mission: get life-changing science to the people who need it most. Read our 2024 Integrated Annual Report: https://lnkd.in/dD5XWWuM 💙
Pages similaires
Parcourir les offres d’emploi
Financement
Ipsen
2 rounds en tout
Voir plus d’informations sur Crunchbase
Dernier round
Dette après introduction en Bourse
Lien Crunchbase externe pour la dernière levée de fonds
545 588 264,00 $US